TAVR Competitors Put Pressure On Edwards To Deliver On New Growth Drivers
This article was originally published in The Gray Sheet
Executive Summary
Edwards is betting on next-generation Sapien devices and efforts towards a transcatheter mitral valve, as Medtronic and other competitors move closer to threatening the firm’s TAVR leadership position.
You may also be interested in...
Edwards Wins Latest Round In TAVI Patent Dispute With Medtronic
A jury in Delaware awarded Edwards $393.6 million in damages plus royalties after determining Medtronic’s CoreValve infringes Edwards’ Cribier patent. While Medtronic might be paying royalties to Edwards for the next several years, Medtronic also got some very positive news last week: FDA approved CoreValve for patients too sick for surgery months earlier than expected.
Medtronic CoreValve Meets Targets In Extreme-Risk Group; Panel Will Not Be Needed, FDA Says
The firm now expects to gain approval for the extreme-risk indication of its transcatheter aortic heart valve months earlier than earlier predicted following well-received pivotal trial data reported last week at the Transcatheter Cardiovascular Therapeutics meeting.
News Briefs: Approvals For Abbott’s MitraClip, Allergan’s Juvéderm; Diagnostics News
FDA approved Abbott’s MitraClip to treat mitral regurgitation and Allergan’s Juvéderm Voluma XC facial filler to temporary correct volume-loss. Hepatitis C testing will be mandatory in New York. More news.